Welcome to our dedicated page for NYXOAH S A news (Ticker: NYXH), a resource for investors and traders seeking the latest updates and insights on NYXOAH S A stock.
Nyxoah SA (NYXH) is a medical technology company that develops and commercializes neuromodulation-based therapies for obstructive sleep apnea (OSA), centered on its Genio hypoglossal neurostimulation system. The Nyxoah news feed on Stock Titan brings together company-issued announcements, regulatory disclosures and market updates that reflect how the business is progressing in its target markets.
Investors following Nyxoah’s news can track updates on U.S. and European commercialization of the Genio system, including surgeon training, account activations and the completion of commercial implants. Company press releases describe milestones such as the commercial launch of Genio in new countries, early U.S. implant activity after FDA approval, and developments in reimbursement coverage with public and private payers.
Nyxoah also regularly reports on its financial position and capital markets activity. News items include quarterly financial and operating results, preliminary revenue updates, private placements, registered direct offerings and convertible bond financings, as well as information on voting rights, share capital and transparency notifications regarding significant shareholdings. These disclosures provide context on how the company funds its commercialization and research plans.
In addition, the news stream features regulatory and legal developments, such as FDA approval of the Genio system for a defined subset of adult OSA patients, CE mark expansions, and intellectual property litigation updates referenced in company filings. By reviewing the NYXH news page, readers can see how Nyxoah communicates progress on clinical, regulatory, commercial and financing fronts over time.
Nyxoah SA announced the issuance of 435,250 new shares on July 9, 2021, following a capital increase tied to its IPO in the U.S. and the exercise of subscription rights. The total share capital now stands at EUR 4,369,902.59, resulting in 25,437,859 voting rights from ordinary shares. Additionally, there are outstanding rights to subscribe to 927,500 shares through various ESOP warrants.
Nyxoah announced the closing of its initial public offering (IPO) on July 7, 2021. The offering included 2,835,000 ordinary shares priced at $30 per share, accumulating total gross proceeds of $85.1 million. Furthermore, underwriters exercised their option to purchase an additional 425,250 shares, increasing gross proceeds to $97.8 million. The closing of this additional share purchase is anticipated on July 9, 2021, subject to standard conditions. Piper Sandler, Stifel, and Cantor acted as joint book-running managers for this offering.
Nyxoah announced the issuance of 2,835,000 new shares on July 7, 2021, related to a capital increase tied to its initial public offering in the United States. This means the share capital now stands at EUR 4,295,126.64, with a total of 25,002,609 voting rights available. The press release outlines the total number of securities and shares following this increase, including various ESOP Warrants that allow holders to subscribe to additional voting securities.
Nyxoah SA has priced its initial public offering (IPO) in the U.S. at US$ 30 per share, totaling US$ 85.1 million in gross proceeds. The offering includes 2,835,000 ordinary shares, with an option for underwriters to purchase an additional 425,250 shares. The IPO is set to close on July 7, 2021, pending conditions. The shares will begin trading on NASDAQ under the symbol NYXH. This marks a significant step in Nyxoah's mission to develop innovative solutions for Obstructive Sleep Apnea.
Nyxoah SA (Euronext Brussels: NYXH) announced the issuance of 60,000 new shares on June 23, 2021, due to the exercise of subscription rights. The company's capital is now EUR 3,808,073.64. The total number of voting rights is 22,167,609, all of which are ordinary shares. Furthermore, various warrants, including 91 from 2013, 365 from 2016, 319 from 2018, and 550,000 from 2020, provide additional rights to subscribe to further shares.